Retatrutide and cancer: what the warning and the studies say
Reviewed 21 sourcesPublished by PepVault
Retatrutide and cancer: where the GLP-1 thyroid warning comes from, who the trials left out, the cancers they counted, and what studies of the class found.

- Last reviewed
- Sources
- 21
- Questions
- 9
- Compounds
- 3
The short answer
No study shows retatrutide causes cancer in people. It is investigational, so it has no label yet. The thyroid cancer warning on approved GLP-1 drugs comes from tumours in rats, and every retatrutide phase 3 trial left out people with a personal or family history of medullary thyroid cancer or MEN 2. Human studies of the class disagree on thyroid cancer and show no rise in most others.
- The boxed warning on Zepbound and Wegovy rests on thyroid C-cell tumours in rats and mice; the labels say the human relevance has not been determined.
- Rodent thyroid C-cells carry the GLP-1 receptor; human and monkey C-cells carry little, and 20 months of liraglutide gave monkeys no C-cell growth.
- The two phase 2 retatrutide trials posted three serious cancer events among 457 people on the drug, none of them thyroid, and none among 115 on placebo.
- For the drug class, a Scandinavian cohort of 145,410 users found no rise in thyroid cancer; a French study and two trial meta-analyses found one.
Evidence: Drug labels and rodent and monkey studies for the thyroid warning; registry records of Eli Lilly's retatrutide trials; observational cohort studies and meta-analyses of randomised trials of the approved GLP-1 drugs; one mouse study of retatrutide and tumours.

Does retatrutide cause cancer?
Nothing so far shows that it does, and the most striking cancer result on retatrutide points the other way, in mice. In a 2025 study, mice that lost weight on retatrutide grew pancreatic tumours 14 times smaller than untreated mice, against 4 times smaller on semaglutide, and lung tumours 17 times smaller19. That is an animal result; no trial has tested retatrutide against cancer in people.
The worry people search for is the thyroid cancer warning printed on every approved GLP-1 weight-loss drug. Retatrutide, a weekly shot that switches on the GLP-1, GIP and glucagon receptors at once (a triple agonist, pepvault.app/glossary/dual-and-triple-agonists), has no label yet, because no regulator anywhere has approved it20. The broader safety record, from pancreatitis to heart events, is in the guide is retatrutide safe.
PepVault's side-effect log keeps each symptom with its date, compound, severity and a note, and the doctor's report puts them beside your logged doses in one document for your clinician. Log it in PepVault

What does the thyroid cancer warning on GLP-1 drugs say?
It is a boxed warning (pepvault.app/glossary/boxed-warning), the FDA's strongest label warning, about one rare cancer. Medullary thyroid carcinoma (MTC) starts in the thyroid's C-cells, which make the hormone calcitonin. Zepbound's label says tirzepatide causes C-cell tumours in rats that rise with dose and treatment length, and that it is unknown whether it does so in humans, because the human relevance has not been determined1. Wegovy's label says the same of semaglutide in mice and rats2.
| What the labels say | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Animals with C-cell tumours | Rats, in a 2-year study; a 6-month study in transgenic mice found none | Mice and rats, over a lifetime |
| Exposure at which tumours rose | Every dose tested, 0.1 to 1 times the human exposure at 15 mg a week | Clinically relevant exposures in both species |
| Who must not use it | A personal or family history of MTC, or MEN 2 | The same |
| Human reports | Human relevance not determined | MTC cases reported after approval in people on liraglutide, too few to show or rule out a cause |
MEN 2 (multiple endocrine neoplasia type 2) is an inherited condition that makes MTC likely, so both labels make it a contraindication (pepvault.app/glossary/contraindication), a reason not to use the drug at all12. Both also say routine calcitonin tests or thyroid ultrasounds are of uncertain value for catching MTC early and can lead to unnecessary procedures, because the test is not specific and thyroid disease is common12.
Why do rats get thyroid tumours on GLP-1 drugs?
Because rat C-cells are built to answer GLP-1, and human ones mostly are not. Novo Nordisk's scientists traced the rodent tumours in 2010: rat and mouse C-cells carry the GLP-1 receptor, and the drugs made them release calcitonin and then multiply, more in rats than in mice. Human and cynomolgus monkey C-cells had little of the receptor, and the drugs set off no calcitonin release in primates3.
In monkeys, 20 months of liraglutide at more than 60 times the human exposure caused no C-cell growth3. In people on liraglutide for two years, calcitonin stayed at the low end of normal, with no more people crossing the 20 pg/ml cut-off than on comparison treatment3. The authors still called the long-term effect on the human thyroid unknown, which is why the warning stays on the label3.
Who did the retatrutide trials leave out because of cancer?
The five phase 3 trials below and the phase 2 obesity trial all turned away anyone with a personal or family history of MTC or MEN 2, the group the approved labels rule out456789. From each trial's ClinicalTrials.gov record, all sponsored by Eli Lilly:
| Trial | People | MTC or MEN 2 history excluded | Other cancer excluded |
|---|---|---|---|
| Phase 2, obesity | 338 | Yes (first-degree relatives) | Active cancer in the last 5 years |
| Phase 2, type 2 diabetes | 281 | Not in the registry's list | Active or untreated cancer |
| TRIUMPH-1, obesity | 2,335 | Yes | Not in the registry's list |
| TRIUMPH-2, obesity and diabetes | 1,152 | Yes | Not in the registry's list |
| TRIUMPH-3, obesity and heart disease | 1,946 | Yes | Not in the registry's list |
| TRANSCEND-T2D-1, diabetes | 537 | Yes | Active or untreated cancer, or remission under 5 years |
| TRIUMPH-Outcomes, heart and kidney (running) | About 10,000 | Yes | Not in the registry's list |
So the results describe people without that thyroid history, and say nothing about anyone with it. Whether retatrutide's label carries the same boxed warning is the FDA's call at review. Retatrutide's own rodent cancer studies are not public, so whether rats on it grow the same tumours is not known outside Lilly.
Did anyone in the retatrutide trials get cancer?
Three people, none with thyroid cancer. The two phase 2 trials are the only ones with results posted to the registry, which lists every serious adverse event, one that puts someone in hospital or threatens life, whatever its cause910:
| Serious event | Obesity trial: retatrutide (267) | Obesity trial: placebo (70) | Diabetes trial: retatrutide (190) | Diabetes trial: placebo (45) |
|---|---|---|---|---|
| Kidney cancer (clear cell renal cell carcinoma) | 1 | 0 | 0 | 0 |
| Melanoma | 0 | 0 | 1 | 0 |
| Basal cell skin cancer | 0 | 0 | 1 | 0 |
| Calcitonin rise reported as serious | 0 | 1 | 0 | 0 |
| Thyroid cancer | 0 | 0 | 0 | 0 |
The kidney cancer came on 4 mg, and the melanoma and skin cancer both in one 4 mg group of 24 people910. Groups this small, followed for 52 weeks and 280 days, give no rate910. No phase 3 trial has posted results yet4567, and the TRIUMPH-1 abstract gives no cancer counts11.
Do GLP-1 drugs raise thyroid cancer risk in people?
The studies split, and the absolute numbers are small either way. Observational studies (pepvault.app/glossary/observational-study) follow people who were prescribed a drug, so other differences between groups can creep in. Meta-analyses pool randomised trials, where the drug was assigned by chance, but trial cancers are few. None of these studies included retatrutide.
| Study | Who | Thyroid cancer result (95% CI) |
|---|---|---|
| France, national health data, 202312 | 2,562 people with thyroid cancer and 45,184 matched controls, all with type 2 diabetes | 1 to 3 years of GLP-1 use: 1.58 times the risk (1.27 to 1.95); MTC 1.78 (1.04 to 3.05) |
| Denmark, Norway and Sweden, 202413 | 145,410 GLP-1 users against 291,667 users of DPP-4 inhibitors, another diabetes drug, followed 3.9 years on average | 0.93 (0.66 to 1.31), no rise; MTC 1.19 (0.37 to 3.86) |
| Meta-analysis of 64 trials, 202414 | Trials of 52 weeks or longer | 1.52 times the odds (1.01 to 2.29); one extra case per 1,349 people treated for 5 years |
| Meta-analysis of 50 trials, 202515 | Diabetes and obesity trials of 52 weeks or longer | 1.55 (1.05 to 2.27) |
A result above 1 means more cancer on the drug; a range that crosses 1 (pepvault.app/glossary/confidence-interval) means no clear difference. In the Scandinavian study, thyroid cancer came at 1.33 cases per 10,000 person-years on GLP-1 drugs and 1.46 on DPP-4 inhibitors, and its upper limit rules out more than a 31% rise13. The 2024 meta-analysis found no clear rise for MTC alone, 1.44 (0.23 to 9.16), and its main finding would flip with one case moved (a fragility index of 1)14. The 2025 authors put a short-term rise in colorectal cancer down to extra tests prompted by the drugs' gut side effects15, and more check-ups can turn up small thyroid cancers the same way.
Do GLP-1 drugs change the risk of other cancers?
Across most cancers, no rise has turned up, and several fell. The 2025 meta-analysis of 50 trials found no difference in overall cancer, an odds ratio of 1.05 (0.98 to 1.13), and fewer uterine cancers in the obesity trials15. Pancreatic cancer, an early worry for the class, did not rise over 7 years in an Israeli study of 543,595 adults with diabetes, against basal insulin17.
The largest study, US health records of 1,651,452 people with type 2 diabetes, compared GLP-1 drugs with insulin and found lower risk in 10 of 13 obesity-linked cancers, among them pancreatic (hazard ratio 0.41), liver (0.47) and colorectal cancer (0.54), and no lower risk of thyroid or postmenopausal breast cancer16. Against metformin, the GLP-1 drugs lowered none of the 13 and came with more kidney cancer, 1.54 (1.27 to 1.87)16. People prescribed insulin tend to have longer, harder diabetes, which is part of why the comparator changes the answer.
Can losing weight lower cancer risk?
Excess body fat causes at least 13 cancers, according to the International Agency for Research on Cancer, the WHO's cancer agency, after a 2016 review of more than 1,000 studies: cancers of the oesophagus, top of the stomach, colon and rectum, liver, gallbladder, pancreas, postmenopausal breast, womb, ovary, kidney and thyroid, plus multiple myeloma and meningioma18.
Thyroid cancer is on that list, so people who start a weight-loss drug carry a raised thyroid cancer risk before the first dose. The mouse study at the top found that retatrutide's protection against tumours held even after the mice stopped the drug and regained weight19. Species note: those were mouse cancer models; whether drug-driven weight loss lowers cancer in people, no trial has yet shown.
What is still unknown about retatrutide and cancer?
- Long-term cancer counts. The phase 3 trials ran 40 to 80 weeks, with an extension to 104 weeks in TRIUMPH-171121. Cancers take years; TRIUMPH-Outcomes, about 10,000 adults, runs into 20298.
- Whether the glucagon arm changes anything. No approved drug switches on the glucagon receptor this way, so the class studies cover GLP-1 drugs and tirzepatide, not a triple agonist.
Who can take a GLP-1 drug with a thyroid history, or after cancer, is the prescriber's decision, made against the label; for retatrutide, which has no label, it is a trial investigator's. Lilly says anyone selling retatrutide to consumers is breaking the law20; the legal side is at pepvault.app/peptides/retatrutide/legal-status.
When to get help The labels name the thyroid signs to report: a lump or swelling in the neck, trouble swallowing, shortness of breath or hoarseness that does not go away; any of these is a reason to see a doctor12.
Sources
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information: boxed warning, 5.1 risk of thyroid C-cell tumours, 13.1 carcinogenesis. Version 40, effective August 28, 2026 (DailyMed; read through openFDA). dailymed.nlm.nih.gov
- Novo Nordisk. WEGOVY (semaglutide) injection, prescribing information: boxed warning, 5.1 risk of thyroid C-cell tumours, 13.1 carcinogenesis (DailyMed; read through openFDA). dailymed.nlm.nih.gov
- Bjerre Knudsen L et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010. PubMed 20203154
- ClinicalTrials.gov NCT05929066 (TRIUMPH-1). A study of retatrutide (LY3437943) in participants who have obesity or overweight (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. clinicaltrials.gov
- ClinicalTrials.gov NCT05929079 (TRIUMPH-2). A study of retatrutide (LY3437943) in participants with type 2 diabetes mellitus who have obesity or overweight (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. clinicaltrials.gov
- ClinicalTrials.gov NCT05882045 (TRIUMPH-3). A study of retatrutide in participants with obesity and cardiovascular disease (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. clinicaltrials.gov
- ClinicalTrials.gov NCT06354660 (TRANSCEND-T2D-1). Retatrutide compared with placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. clinicaltrials.gov
- ClinicalTrials.gov NCT06383390 (TRIUMPH-Outcomes). The effect of retatrutide once weekly on cardiovascular and kidney outcomes in adults living with obesity (phase 3; sponsor Eli Lilly and Company). Eligibility criteria and status. clinicaltrials.gov
- ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or overweight (phase 2; sponsor Eli Lilly and Company). Eligibility and results record: serious adverse events. clinicaltrials.gov
- ClinicalTrials.gov NCT04867785. A study of LY3437943 in participants with type 2 diabetes (phase 2; sponsor Eli Lilly and Company). Eligibility and results record: serious adverse events. clinicaltrials.gov
- Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. PubMed 42814954
- Bezin J et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023. PubMed 36356111
- Pasternak B et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024. PubMed 38683947
- Silverii GA et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024. PubMed 38018310
- Silverii GA et al. GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2025. PubMed 40437949
- Wang L et al. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024. PubMed 38967919
- Dankner R et al. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open. 2024. PubMed 38175642
- Lauby-Secretan B et al.; IARC Handbook Working Group. Body fatness and cancer: viewpoint of the IARC Working Group. N Engl J Med. 2016. PubMed 27557308
- Marathe SJ et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. NPJ Metab Health Dis. 2025. PubMed 40094000
- Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (TRANSCEND-T2D-2). Press release, Oct 28, 2026. prnewswire.com
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Press release, May 21, 2026. prnewswire.com
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.